Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nesrin Mogulkoc

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Frontiers in Medicine|January 10, 2022
Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE CountriesAbigél Margit Kolonics-Farkas, Martina Šterclová, Nesrin Mogulkoc, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|January 22, 2025
Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping reviewAnouk Delameillieure, Vivien Somogyi, Silja Schenk, et al.
Respiratory Medicine|September 10, 2024
Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based studyMartina Koziar Vašáková, Jakub Gregor, Nesrin Mogulkoc, et al.
Respiratory Research|January 10, 2020
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosisTanja Tran, Martina Šterclová, Nesrin Mogulkoc, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
ERJ Open Research|March 18, 2026
The COCOS-IPF core outcome set for idiopathic pulmonary fibrosis/progressive pulmonary fibrosis care: a mixed-method multi-perspective approachSofie Breuls, Vivien Somogyi, Silja Schenk, et al.
Archivos De Bronconeumologia|December 30, 2023
The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE RegistryJakub Gregor, Yochai Adir, Martina Šterclová, et al.
The Lancet. Respiratory Medicine|August 22, 2020
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Steven D Nathan, Wim A Wuyts, et al.
Annals of the American Thoracic Society|April 12, 2021
Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary FibrosisJean Pastre, Scott D Barnett, Inga Ksovreli, et al.
Biomedicines|November 27, 2025
Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health EquityNóra M Tóth, Mordechai R Kramer, Martina Šterclová, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Frontiers in Medicine|January 10, 2022
Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE CountriesAbigél Margit Kolonics-Farkas, Martina Šterclová, Nesrin Mogulkoc, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|January 22, 2025
Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping reviewAnouk Delameillieure, Vivien Somogyi, Silja Schenk, et al.
Respiratory Medicine|September 10, 2024
Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based studyMartina Koziar Vašáková, Jakub Gregor, Nesrin Mogulkoc, et al.
Respiratory Research|January 10, 2020
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosisTanja Tran, Martina Šterclová, Nesrin Mogulkoc, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
ERJ Open Research|March 18, 2026
The COCOS-IPF core outcome set for idiopathic pulmonary fibrosis/progressive pulmonary fibrosis care: a mixed-method multi-perspective approachSofie Breuls, Vivien Somogyi, Silja Schenk, et al.
Archivos De Bronconeumologia|December 30, 2023
The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE RegistryJakub Gregor, Yochai Adir, Martina Šterclová, et al.
The Lancet. Respiratory Medicine|August 22, 2020
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trialJürgen Behr, Steven D Nathan, Wim A Wuyts, et al.
Annals of the American Thoracic Society|April 12, 2021
Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary FibrosisJean Pastre, Scott D Barnett, Inga Ksovreli, et al.
Biomedicines|November 27, 2025
Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health EquityNóra M Tóth, Mordechai R Kramer, Martina Šterclová, et al.
Pageof 6